International League Against Epilepsy

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting

Retrieved on: 
화요일, 11월 21, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Medicine, International League Against Epilepsy, Dravet syndrome, American Epilepsy Society, Annual general meeting, Therapy, Language, Patient, Movement, Seizure, MB, Speech, Neurology, Epilepsy, AES, Safety, Pharmaceutical industry, Pediatric nursing

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that presentations related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2023 Annual Meeting, taking place December 1 – 5, in Orlando, Florida.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that presentations related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2023 Annual Meeting, taking place December 1 – 5, in Orlando, Florida.
  • The company is advancing STK-001 as potentially the first medicine to address the genetic cause of Dravet syndrome.
  • “People living with Dravet syndrome typically experience high rates of seizures and debilitating effects on neurodevelopment, including behavioral and developmental delays, movement and balance issues, and delayed language and speech, among other life-altering challenges, which current treatments do not adequately address,” said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics.
  • “We look forward to sharing the findings from more than 3 years of clinical studies, including important new data from the longest and largest prospective natural history study of patients with Dravet syndrome, which showed that despite treatment with multiple anti-seizure medicines, most patients continued to experience convulsive seizures over 24 months and that gaps in neurodevelopment persist between children with Dravet syndrome and their neurotypical peers.

Misophonia Research Fund Crosses $10M Invested: Announces New Cohort of Funded Researchers and Executive Director

Retrieved on: 
화요일, 10월 31, 2023
Mental Health, Health, Neurology, Other Science, General Health, Research, Science, Trigger, Attention, Behavior, Doctor of Philosophy, Epilepsy, Milken Institute, Multimedia, MRF, Directorate of Research and Civil Affairs, Growth, Acceleration, Fund, Aircraft pilot, Milken Institute School of Public Health, Letter, Memory, International League Against Epilepsy, Pharmaceutical industry, Management, Misophonia

Today, the Fund announces six recipients of its latest round of grants supporting scientific investigators who seek to characterize misophonia and develop new therapeutic strategies.

Key Points: 
  • Today, the Fund announces six recipients of its latest round of grants supporting scientific investigators who seek to characterize misophonia and develop new therapeutic strategies.
  • Powered by the uptick in misophonia investment and researcher participation, the Fund also welcomes its first Executive Director, Lauren Harte-Hargrove, PhD, who will work as a dedicated leader of the Fund to catalyze progress in misophonia.
  • “Our nationwide search landed the perfect person to lead the Misophonia Research Fund.
  • We’re thrilled to welcome her as MRF’s Executive Director and look forward to working together to advance misophonia research,” said Diane Miller, President of the REAM Foundation.

NEURELIS TO PRESENT ANALYSES OF VALTOCO® (diazepam nasal spray) CIV HIGHLIGHTING EFFECTS ON TIMING OF SEIZURES AT THE 35TH INTERNATIONAL EPILEPSY CONGRESS

Retrieved on: 
목요일, 8월 31, 2023
Online, Epilepsy, PM, International Bureau for Epilepsy, IBE, ASDS, World Organization of the Scout Movement, International League Against Epilepsy, Interval, Patient, Seizure, SAN, Post hoc analysis, IEC, Congress, FDA, ILAE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Treatment, Food, Diazepam, Pharmaceutical industry, Dietary supplement

SAN DIEGO, Aug. 31, 2023 /PRNewswire/ -- Neurelis, Inc. will present additional clinical findings from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in people with epilepsy for ages 6 to 65 at the 35th International Epilepsy Congress (IEC) in Dublin, Ireland, September 2 to 6. The congress is organized by the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE).

Key Points: 
  • The congress is organized by the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE).
  • "Despite availability of chronic, daily oral medications to help control seizures, many patients continue to experience acute repetitive seizures," said Adrian L. Rabinowicz, M.D., Neurelis Chief Medical Officer.
  • These data demonstrate that over a 12-month period, a statistically significant increase in the time between seizure clusters was observed with administration of diazepam nasal spray.
  • This change in SEIVAL appears to be independent of age or changes in concomitant ASDs and may reflect a beneficial effect of intermittent rescue therapy with diazepam nasal spray.

Vial Announces New Central Nervous System Scientific Advisory Board Member, Dr. Jacqueline French of the Epilepsy Study Consortium and NYU Grossman School of Medicine.

Retrieved on: 
금요일, 1월 13, 2023
NYU Langone Health, SAB, EEG, Mount Sinai Hospital, CNS, International League Against Epilepsy, AAN, MD, Epilepsy, Drug discovery, National Association of Epilepsy Centers, Patient, Yale University, American Academy, American Academy of Neurology, Research, SAN, Brown University, NYU, Fine chemical, Pharmaceutical industry, Vial, Neurology

Dr. French is a professor of neurology at the NYU Grossman School of Medicine, co-director of epilepsy clinical trials for NYU Langone Health's Comprehensive Epilepsy Center, and president, director, and founder of The Epilepsy Study Consortium.

Key Points: 
  • Dr. French is a professor of neurology at the NYU Grossman School of Medicine, co-director of epilepsy clinical trials for NYU Langone Health's Comprehensive Epilepsy Center, and president, director, and founder of The Epilepsy Study Consortium.
  • After receiving her medical education at Brown University, she completed a residency in neurology at Mount Sinai Hospital in New York.
  • Thereafter, she pursued further training through a fellowship in EEG and epilepsy at Mount Sinai Hospital and Yale University.
  • We are pleased to welcome Dr. French as she is an esteemed leader in clinical neurology research," said Simon Burns, CEO and Co-founder of Vial.

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

Retrieved on: 
금요일, 12월 2, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Linda, Safety, International League Against Epilepsy, Intellectual disability, Pharmacokinetics, Fenfluramine, DS, Patient, Adolescence, Language, Hospital, AES, Phase, Caregiver, Quality of life, Associate, Movement, Therapy, EMA, Cognition, SUDEP, Development of the nervous system, Lurie Children's Hospital, Dravet syndrome, Seizure, Even and odd functions, Syndrome, Autonomic nervous system, Helen Cross, Disease, Stoke, Annual general meeting, Diagnosis, Death, Ann, MB, Sleep, Medicine, SCN1A, Government budget balance, ASO, DMPK, OLE, Plasma, Prognosis, American Epilepsy Society, Observational study, FDA, Senior, Feinberg School of Medicine, Neurology, European Journal of Paediatric Neurology, Risk, Cerebrospinal fluid, Pharmaceutical industry, Vaccine, Medical imaging, Pediatric nursing, BioAnalyt, Epilepsy

A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.

Key Points: 
  • A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.
  • STK-001 represents an entirely new approach to treatment, one that aims to treat the syndrome, not just the seizures.
  • Topline data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies showed single and multiple doses of STK-001 up to 45mg were well-tolerated.

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
화요일, 11월 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Linda, Development of the nervous system, American Epilepsy Society, Dravet syndrome, Risk, Cognition, Therapy, International League Against Epilepsy, Ann, Government budget balance, OLE, Stoke, Neurology, Cerebrospinal fluid, Associate, SUDEP, Patient, Intellectual disability, Hospital, Autonomic nervous system, Caregiver, Movement, Medicine, European Journal of Paediatric Neurology, Prognosis, ASO, Seizure, Plasma, FDA, Diagnosis, EMA, Disease, Safety, Sleep, Adolescence, Lurie Children's Hospital, 2021 Essex County Council election, DMPK, AES, MB, Language, Annual general meeting, Senior, SCN1A, Death, Quality of life, Feinberg School of Medicine, Pharmaceutical industry, Paint, Vaccine, Epilepsy, Pharmacokinetics, Pediatric nursing, BioAnalyt

The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.

Key Points: 
  • The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.
  • STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials.
  • Stokes first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

Cerecin Announces Abstract on New Infantile Spasms Data Accepted for Oral Presentation at the International League Against Epilepsy EME Congress 2022

Retrieved on: 
목요일, 11월 3, 2022
Migraine, Ketone bodies, Therapy, Epilepsy, Neurology, Congress, GLOBE, Poster, International League Against Epilepsy, Plasma, Peripheral nervous system, Spasm, Pharmaceutical industry

SINGAPORE and DENVER, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced that a poster showcasing new data on investigational CER-0001 (tricaprilin) in Infantile Spasms (also known as West Syndrome) has been accepted for virtual oral presentation at the hybrid International League Against Epilepsy EME Congress, held in Riyadh from November 16-19, 2022.

Key Points: 
  • SINGAPORE and DENVER, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced that a poster showcasing new data on investigational CER-0001 (tricaprilin) in Infantile Spasms (also known as West Syndrome) has been accepted for virtual oral presentation at the hybrid International League Against Epilepsy EME Congress, held in Riyadh from November 16-19, 2022.
  • The data will be presented by Cerecins Chief Medical Officer, Dr. Marc Cantillon.
  • Cerecin is supported by two multinational partners, Nestle S.A. (NSRGY), and Wilmar International Limited (F34.SI).
  • CER-0001, also known as tricaprilin, is a specific medium chain triglyceride that Cerecin is developing for a range of neurological indications including Alzheimers disease, migraine and infantile spasms.

Wiley Launches ‘Partner Solutions’ Division in Research to Support the Transition to Open Access Publishing

Retrieved on: 
월요일, 10월 17, 2022
Research, Publishing, Entertainment, Communications, Books, Other Education, University, Primary, Secondary, Science, Education, Knowledge, LinkedIn, Editorial, Mission statement, General manager, Diagnosis, Society, Education, Organization, International League Against Epilepsy, NYSE, Library, Twitter, Frankfurt Book Fair, Electrical engineering technology, Institute, Electronics, Goal, Epilepsy, ACM, Publishing, Industry, Wiley-Blackwell, AAAS, American Association, Association, Fred Brooks, IEEE, American Association of Neuromuscular & Electrodiagnostic Medicine, Classification, Manuscript, Electricity, Solution, Â, Research Institute for Advanced Computer Science, Leadership, Management, Pharmaceutical industry, Facebook, Research

In the run-up to the Frankfurt Book Fair, Wiley (NYSE: WLY), a global leader in research and education, today announced Wiley Partner Solutions , a new division within its Research business.

Key Points: 
  • In the run-up to the Frankfurt Book Fair, Wiley (NYSE: WLY), a global leader in research and education, today announced Wiley Partner Solutions , a new division within its Research business.
  • Wiley Partner Solutions serves associations, scientific publishers, societies and corporations as they transform their business strategies and publishing processes in the open research era.
  • Wiley Partner Solutions delivers a broad array of digital platforms, publishing solutions, and services to help partners scale, collaborate, and accelerate their publishing programs, while at the same time supporting the value chain of scholarly publishing.
  • Wiley Partner Solutions will operate separately from Wileys Research Publishing business and will be reported as Research Solutions or Research Partner Solutions in the Companys public filings and financial statements.

NEURELIS TO HIGHLIGHT VALTOCO (DIAZEPAM NASAL SPRAY) CIV DEVELOPMENT PROGRAM Updates AT 16TH EILAT CONFERENCE

Retrieved on: 
화요일, 5월 31, 2022
Food, Coma, Seizure, Mania, Pharmacokinetics, CNS, Conference, International League Against Epilepsy, Headache, Schizophrenia, Metabolic acidosis, Somnolence, Hemangioma, Suicidal ideation, Anticonvulsant, Hypoventilation, Depression, Boxed warning, SAN, Drug, Diazepam, Administration, Death, Science, Multimedia, Health, Patient, ROCK, Adult, Schedule, FDA, Status epilepticus, Epilepsy, Benzodiazepine, Central nervous system, AND, Therapy, Risk, CCMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AED, View, Intraocular pressure, Device, Benzyl alcohol, Contraindication, Safety, Technology, Glaucoma, Behavior, Pharmaceutical industry, Dietary supplement, Birth control, Medicine, Gustav Neuring

The VALTOCO development program included 175 patients and treated more than 4,000 seizures.

Key Points: 
  • The VALTOCO development program included 175 patients and treated more than 4,000 seizures.
  • Currently, the Stellina trial, a Phase 1/2a open-label study of VALTOCO, is investigating pharmacokinetics, safety, and tolerability in pediatric epilepsy patients ages 2 to 5.
  • For more information on Neurelis, please visit www.neurelis.com .For the latest scientific information on VALTOCO, please visit www.neurelismedicalaffairs.com .
  • For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.